Sunday, 23 January 2022

Australia's most trusted
source of pharma news

Sunday, 23 January 2022

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (9)

Sales & Customer Relations (26)

Access & Reimbursement (1)

Clinical & Medical, R&D (17)

Regulatory, Pharmacovigilance & QA (6)

Other (16)


Noxopharm in trading halt

Posted 15 November 2021 PM

Sydney-based Noxopharm has called a trading halt on the ASX after receiving one of the largest grants ever handed out to a biotech for a single drug program from the Australian Government's Medical Research Future Fund (MRFF).

This morning, Noxopharm was awarded $8.79 million through the MRFF's Rapid Applied Research Translational initiative to cover the cost of a clinical trial, part of its Chemotherapy Enhancement Program (CEP), investigating the combination of Veyonda and standard of care chemotherapy drug, doxorubicin, in patients with soft tissue sarcoma (STS).

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.